David A. Cavazos

David A. Cavazos

Auto-generated profile, based on publicly available information

David A. Cavazos

UT Health San Antonio, San Antonio, TX, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2014 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
TWTongde Wu
Tongde Wu
BHBryan G. Harder
Bryan G. Harder
PWPak K. Wong
Pak K. Wong
JLJulie E Lang
Julie E Lang
DZDonna D. Zhang
Donna D. Zhang

25 February 2011 in The Prostate
Verified
Journal Article
Closed access
PDF file
DCDavid A. Cavazos
David A. Cavazos
RPRamona S. Price
Ramona S. Price
SAShruti S. Apte
Shruti S. Apte
LDLinda A. Degraffenried
Linda A. Degraffenried

1 September 2006 in Rejuvenation Research
Verified
Journal Article
Closed access
ASAisha Siddiqa
Aisha Siddiqa
DCDavid A. Cavazos
David A. Cavazos
RMRobert A. Marciniak
Robert A. Marciniak
Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have included both targeting components of telomerase (the protein component, TERT, or the RNA component, TERC) or by directly targeting telomere DNA structures. Recently a combination telomerase inhibition therapy has been studied also. The TERT promoter has been used to selectively express cytotoxic gene(s) in cancer cells and a TERT vaccine for immunization against telomerase has been tested. The 10% to 15% of immortalized cancer cells that do not express telomerase use a recombinationbased mechanism for maintaining telomere structures that has been called the alternative lengthening of telomeres (ALT). In view of the increasing study of telomerase inhibitors as anticancer treatments, it will be crucial to determine whether inhibition of telomerase will select for cancer cells that activate ALT mechanisms of telomere maintenance.

1 January 2007 in Cancer Investigation
Verified
Journal Article
Closed access
JSJessica Silva-fisher
Jessica Silva-fisher
DCDavid A. Cavazos
David A. Cavazos
EDElissa Donzis
Elissa Donzis
WFWilliam E. Friedrichs
William E. Friedrichs
RMRobert Marciniak
Robert Marciniak
LDLinda A. Degraffenried
Linda A. Degraffenried
The Akt kinase is a serine/threonine protein kinase that has been implicated in mediating a variety of biological responses, is associated with a poor pathophenotype in breast carcinoma, and is involved in hormone and chemotherapy resistance, including resistance to the antiestrogen, tamoxifen. Akt promotes cell survival by phosphorylating and inactivating proapoptotic proteins and increasing the transcription of survival genes. To explore the role that specific components of the Akt kinase pathway play in the cellular response to tamoxifen, we transfected MCF-7 cells with an expression plasmid for a constitutively active Akt. We found that MCF-7 breast cancer cell lines expressing a constitutively active Akt are able to proliferate under reduced estrogen conditions and are resistant to the growth inhibitory effects of tamoxifen, both in vitro as well as in vivo in xenograft models. Initial analysis of the molecular responses in the Akt/MCF-7 xenografts to tamoxifen suggests that high Akt activity alters apoptotic responses to tamoxifen. Control MCF-7 xenografts demonstrated activation of the proapoptotic forkhead (FKHR) transcription factor in response to tamoxifen treatment, while the xenografts expressing the constitutively active Akt transgene demonstrated no alterations in FKHR expression. In addition, TUNEL analysis demonstrated higher levels of apoptosis in the control xenografts in response to tamoxifen treatment compared to the Akt xenografts. Inhibition of Akt activity in vitro restored apoptotic responses to tamoxifen in the Akt/MCF-7 cells to those observed in the control cells. These data suggest that alteration of survival responses is an important mechanism by which Akt confers resistance to tamoxifen.

1 August 2015
Verified
Conference Paper
Closed access
GSGangadhara R Sareddy
Gangadhara R Sareddy
AGAleksandra Gruslova
Aleksandra Gruslova
DCDavid A. Cavazos
David A. Cavazos
RTRajeshwar R. Tekmal
Rajeshwar R. Tekmal
ABAndrew J. Brenner
Andrew J. Brenner
RVRatna Vadlamudi
Ratna Vadlamudi
Glioblastoma (GBM) is the most common type of primary brain tumor with poor prognosis. A gender bias exists in the development of GBM with incidence of developing GBM is greater in males compared to females. Epidemiological studies and several lines of evidence suggest tumor suppressive role of female sexual hormone estrogen on brain tumors. However, estrogen as potential therapy for GBM has limited therapeutic application due to safety concerns including breast cancer, uterine cancer, heart disease, and feminization in men. Therefore alternative agents that mimic estrogen effects will have potent utility in treating GBM. Estrogen effects are mediated though its cognate receptors ERα and ERβ and ERβ functions as a tissue-specific tumor suppressor. Recent studies identified a synthetic LY500307 as a selective ERβ agonist (developed by Eli Lilly and Company) with an excellent preclinical profile and is currently in clinical trials for treating Schizophrenia. We recently showed that ERβ is the major ER subtype expressed in GBM. The objective of this study is to determine the therapeutic effects of novel ERβ agonist LY500307 using both in vitro and orthotopic preclinical models and to determine its mechanism(s) of action. In this study, we have tested the therapeutic efficacy of LY500307 using several established as well as patient derived GBM cells. Treatment of LY500307 significantly reduced the proliferation of GBM cells with no activity on normal astrocytes suggesting its tumor specific effects. Overexpression of ERβ reduced proliferation of GBM cells and knockdown of ERβ compromised the treatment effect of LY500307 further suggesting the specificity. RNA sequencing analysis of LY500307 treated and untreated GBM cells revealed several novel pathways related to apoptosis, cell cycle, stem cells and differentiation that were significantly modulated by LY500307. Mechanistic studies revealed that LY500307 mediated apoptosis of GBM involve genes activated by both ERβ- classical as well as AP1 mediated non-classical pathways and also involve p38MAPK and JNK pathways. Since Glioma Stem Cells (GSCs) are implicated in tumor initiation, invasion and therapy resistance of GBM, we also tested the effect of LY500307 on GSCs. LY500307 treatment significantly inhibited the proliferation, neurosphere formation and self-renewal of GSCs and also resulted in the loss of stemness of GSCs and induction of differentiation and apoptosis. Further, LY500307 treatment significantly reduced the tumor growth in in vivo orthotopic GBM models and promoted apoptosis of tumors. Together, our results demonstrate that LY500307 as a potential therapeutic agent for treatment of GBM. Since LY500307 has good blood-brain barrier permeability and less neuronal toxicity, it can be readily transferred to clinical use with current radiation and chemotherapies, thereby providing an additional tool for enhancing survival in GBM patients.

6 November 2017 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
VPVaibhav B. Patel
Vaibhav B. Patel
AMAsif Maknojia
Asif Maknojia
MGMichael Garcia
Michael Garcia
DCDavid Cavazos
David Cavazos
AGAleksandra Gruslova
Aleksandra Gruslova
JFJohn Floyd
John Floyd
Meningioma account for 36% of intracranial tumors and 4.7-7.2% demonstrate aggressive clinical behavior. Current treatments are limited to surgery and radiation. We investigated hypoxia activated prodrugTH302 in patient-derived xenograft model of malignant meningioma. Female athymic nude mice were implanted subcutaneously with human meningioma tissue obtained intraoperatively. After 80 days of tumors growth animals were randomized into four groups 1) Control(n=1), 2) XRT (n=4), 3) TH302(n=5), and 4) XRT+TH302(n=4). Mice were either focally radiated using LINAC system in five fractions of 3Gy given daily to a total of 15 Gy, treated with TH302 at 50mg/kg started on day 3 of radiation for 9 doses every other day or combination of both. Tumor volume was measured by a digital caliper until endpoint of 4000 mm3 was reached. H&E, IHC and western blot analysis were performed to further elucidate mechanism of action in meningioma. Additionally, CH157MN meningioma cell line is being used for drug concentration screening (0.1uM - 500uM) to determine IC50 under normaxia and hypoxia conditions using MTT assay. Tumor growth in 1)Control: 1199 mm3 to 4371 mm3 in 35 days, 2)XRT: 890 mm3 to 4220 mm3 in 91 days, 3)TH302: 660 mm3 to 4894 mm3 in 130 days and 4)XRT+TH302: 890 mm3 to 4266 mm3 in 155 days. FFPE H&E and CA9 stained sections show increase in necrotic regions while decrease in hypoxia in XRT/TH302 vs XRT. Western blot showed increase in Chk1, Rad51, and Polβ in XRT+TH302. Our in vivo study shows that mice treated with XRT+TH302 compared to XRT alone have prolonged survival with p<0.0206 with decreased rate of tumor growth likely from TH302-dependent DNA damage of hypoxic cells resulting in cell death.